

Congress of the United States
House of Representatives

SELECT SUBCOMMITTEE ON THE CORONAVIRUS PANDEMIC

2157 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6143

Majority (202) 225-5074
Minority (202) 225-5051

March 5, 2024

Daniel Jernigan, M.D., M.P.H.
Director
National Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control & Prevention
395 E. Street, S.W.
Washington, D.C. 20024
[TRANSMITTED VIA EMAIL]

Dear Dr. Jernigan:

Enclosed are post-hearing questions that have been directed to you and submitted to the official record for the Select Subcommittee on the Coronavirus Pandemic hearing that was held on Thursday, February 15, 2024 titled “Assessing America’s Vaccine Safety Systems, Part 1.”

To ensure a complete hearing record, please return your written response to the Committee on or before Tuesday, March 19, 2024, including each question in full as well as the name of the member. Your response should be addressed to the Committee office at 2157 Rayburn House Office Building, Washington, D.C. 20515. Please also send an electronic version of your response by email to Marie Policastro, Clerk for the Select Subcommittee, at marie.policastro@mail.house.gov.

Thank you for your prompt attention to this request. If you need additional information or have other questions, please contact Committee on Oversight and Accountability staff at (202) 225-5074.

Sincerely,



Brad Wenstrup, D.P.M.
Chairman

cc: The Honorable Raul Ruiz, Ranking Member
Select Subcommittee on the Coronavirus Pandemic

Questions for Daniel Jernigan
Director
National Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention (CDC)

February 15, 2024: Select Subcommittee on the Coronavirus Pandemic hearing titled
“Assessing America’s Vaccine Safety Systems, Part 1”

Questions from Rep. Debbie Lesko

- 1) How many of the VAERS reports about the COVID vaccine have been fully investigated?
- 2) How many of the VAERS reports about the COVID vaccine have been confirmed?

Questions from Rep. Michael Cloud

1. Do you own individual stocks in any of the following companies?
 - a. Pfizer
 - b. Moderna
 - c. BioNTech
 - d. Novavax

2. Several of the COVID-19 vaccines have received full FDA approval and are no longer being used under emergency authorization. Is it standard practice for the countermeasures that have received such approval to continue receiving liability protection under the PREP Act and for injury claims regarding these countermeasures to be compensated via the Countermeasures Injury Compensation Program?

3. Have any CDC employees who had any role in formulating or promoting the CDC's guidance regarding the COVID-19 vaccines at any point left the CDC to work at any of the following companies within the last four years?
 - a. Pfizer
 - b. Moderna
 - c. BioNTech
 - d. Novavax